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Abstract
Background: Molecular typing is integral for identifying Pseudomonas aeruginosa strains that may be shared
between patients with cystic fibrosis (CF). We conducted a side-by-side comparison of two P. aeruginosa genotyping
methods utilising informative-single nucleotide polymorphism (SNP) methods; one targeting 10 P. aeruginosa SNPs and
using real-time polymerase chain reaction technology (HRM10SNP) and the other targeting 20 SNPs and based on the
Sequenom MassARRAY platform (iPLEX20SNP).
Methods: An in-silico analysis of the 20 SNPs used for the iPLEX20SNP method was initially conducted using sequence
type (ST) data on the P. aeruginosa PubMLST website. A total of 506 clinical isolates collected from patients attending
11 CF centres throughout Australia were then tested by both the HRM10SNP and iPLEX20SNP assays. Type-ability and
discriminatory power of the methods, as well as their ability to identify commonly shared P. aeruginosa strains, were
compared.
Results: The in-silico analyses showed that the 1401 STs available on the PubMLST website could be divided into 927
different 20-SNP profiles (D-value = 0.999), and that most STs of national or international importance in CF could be
distinguished either individually or as belonging to closely related single- or double-locus variant groups. When applied
to the 506 clinical isolates, the iPLEX20SNP provided better discrimination over the HRM10SNP method with 147
different 20-SNP and 92 different 10-SNP profiles observed, respectively. For detecting the three most commonly
shared Australian P. aeruginosa strains AUST-01, AUST-02 and AUST-06, the two methods were in agreement for 80/81
(98.8%), 48/49 (97.8%) and 11/12 (91.7%) isolates, respectively.
Conclusions: The iPLEX20SNP is a superior new method for broader SNP-based MLST-style investigations of
P. aeruginosa. However, because of convenience and availability, the HRM10SNP method remains better suited
for clinical microbiology laboratories that only utilise real-time PCR technology and where the main interest is
detection of the most highly-prevalent P. aeruginosa CF strains within Australian clinics.
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Background
Cystic fibrosis (CF) is the most common, lethal autosomal
recessive disease in Caucasian populations [1]. Most CF
patients die in their third or fourth decade from com-
plications of chronic pulmonary infection. Pseudomonas
aeruginosa is the predominant pathogen and once it is
established within the lungs of CF patients it is rarely
eradicated, resulting in increased treatment requirements
and an accelerated decline in lung function, quality of
life and survival [2]. While many CF patients acquire
P. aeruginosa from their natural environment, there is
also evidence of person-to-person transmission occur-
ring [3]. Delaying or even preventing P. aeruginosa infec-
tion is an important management goal. Consequently,
determining P. aeruginosa acquisition pathways and con-
ducting longitudinal surveillance using molecular-based
typing techniques are critical steps for developing novel
interventions and evidence-based infection control pol-
icies to interrupt the spread of transmissible strains within
the CF community [4-6].
Recently, multi-locus sequence typing (MLST) has
emerged as an important epidemiological tool for inves-
tigating temporally and geographically diverse bacteria
[7]. It offers a standardised, reproducible and portable
typing approach that allows reliable data comparisons by
way of a publically accessible web-based database [7,8].
However, when applied to large-scale investigations in-
volving many hundreds or thousands of isolates it is
limited by cost and complexity [9]. To circumvent these
problems, some researchers have utilised defined sets of
informative single nucleotide polymorphisms (SNPs)
derived from MLST data to infer genetic relationships
between isolates. In essence, it is a narrowed MLST ap-
proach and has been applied to various organisms, includ-
ing pathogens relevant to CF, such as methicillin-resistant
Staphylococcus aureus and P. aeruginosa [10-13]. Selec-
tion of appropriate SNPs, including SNP location and total
numbers, is an integral facet of informative SNP strat-
egy to ensure a discriminatory, yet cost-effective, typing
scheme. However, once an informative SNP approach tai-
lored to a particular purpose is implemented, it will theor-
etically have limitations in terms of discriminatory power
if used beyond its original objectives.
Previously, we have shown that SYBR Green-based real-
time polymerase chain reaction (PCR) assays and high-
resolution melting (HRM) curve analysis targeting 10
key SNPs in five housekeeping genes (HRM10SNP) can
detect the major P. aeruginosa strains shared by CF patients
in Queensland, Australia [10]. Furthermore, we demon-
strated recently that this form of typing can be adapted
to the iPLEX MassARRAY platform to allow high-
throughput genotyping [14]. However, based on the high
levels of genetic diversity observed amongst shared
P. aeruginosa strains in the national Australian CF study
[15] and also internationally amongst patients attending
CF clinics [16], we sought to reassess the HRM10SNP and
investigate alternative SNP-based typing strategies for
identifying a broader range of P. aeruginosa strains.
Methods
Clinical isolates
To ensure representative and geographical diversity, 506
clinical isolates were sourced randomly from a biobank
of CF isolates collected as part of an ongoing national
study of shared P. aeruginosa strains involving patients
attending 11 CF clinics in Australia’s five largest cities
[15] (Additional file 1: Table S1). Isolates were incubated
on horse blood agar plates for 24-hours at 37°C. Once
purity was confirmed, heat-denatured suspensions of each
isolate were prepared as described previously [10].
HRM10SNPAssay
The HRM10SNP assay was performed for each isolate
as described previously [10]. Briefly, each heat-denatured
isolate was tested using 10 individual PCR reactions
using the qPCR SuperMix-UDG (Invitrogen Australia,
Mulgrave, NSW, Australia) on the Rotorgene-6000
(Qiagen, Doncaster, Victoria, Australia). Results from
each reaction were compiled to provide a 10-SNP profile
for each isolate. As reported previously, isolates with 10-
SNP profiles of CTCCTCGGCA, TCTTTCGGTA and
CCTCCTGATG were determined to be AUST-01, AUST-
02 and AUST-06, respectively [10].
20-SNP iPLEXMassARRAY(iPLEX20SNP)
The iPLEX20SNP assay was based on the Sequenom
MassARRAY platform (Sequenom, Brisbane, Queensland,
Australia) and was a modification of a method described
previously [14]. Here, SNPs were derived by analysing se-
quence data on the P. aeruginosa PubMLST website [17].
Briefly, 1070 concatenated sequences of P. aeruginosa
housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA,
and trpE) were downloaded (12 January, 2012) and in-
vestigated for informative SNPs with the aid of the
Minimum SNPs software version 2043 [18] and by man-
ual sorting (using BioEdit version 7.0.9.0). Overall, 20
SNPs were identified and SNP positions based on the
2882 bp concatenated P. aeruginosa MLST sequence are
listed in Tables 1 and 2. Of these 20 SNPs, four were iden-
tical to SNPs used in the HRM10SNP assay; SNPs at sites
7, 322, 1152 and 2551 of the iPLEX20SNP assay (Tables 1
and 2) overlapped with SNPs 1, 2, 5 and 10 from the
HRM10SNP assay.
Primers and extension primers for each of the 20 SNPs
in the iPLEX20SNP were designed as reported previ-
ously [14]. All 20 target SNPs were designed for use in
a single multiplex well using Assay Designer 4.0 soft-
ware (Sequenom, Herston, Queensland, Australia). The
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24 amplification primers and 21 extension primers used
for SNP detection are listed in Tables 1 and 2. Two exten-
sion primers with overlapping mass were used for SNP
site 416 to accommodate a known proximal SNP variation
(Table 2).
SNP detection by MassARRAY was performed as out-
lined formerly [14], with the following modifications:
(1) following the initial PCR, residual PCR Taq poly-
merase was removed by protease digestion; 1 μl of protease
solution (1.07 AU, Qiagen, Doncaster, Victoria, Australia)
was added to each PCR reaction and the mixture incubated
at 55°C for 30 min followed by an inactivation at 95°C for
5 min; and (2) the single base extension step was performed
using the iPLEX Pro Extension Reaction Kit (Sequenom,
Herston, Queensland, Australia) following manufacturer’s
instructions. SNPs were coded from 1 to 20 to generate a
20 SNP code. The 20-SNP profiles were then interpreted
using the data compiled from in-silico analysis of the
P. aeruginosa MLST database, as described below, to
provide predicted sequence types (STs). Characterised iso-
lates representative of each SNP were used as reference
controls for each test run.
In-silico analysis of 20-SNP profiles from the MLST
database
For final result analyses, 1779 concatenated sequences of
P. aeruginosa housekeeping genes were again down-
loaded (13th December 2012) and reanalysed. The 1779
P. aeruginosa sequences yielded 1401 different STs. The
predicted ability of the 20-SNP profile to distinguish
these 1401 STs was investigated, as was its ability to dis-
tinguish STs of national: AUST-01 (ST- 649), AUST-02
(ST-775), AUST-03 (ST-242), AUST-04 (ST-788), AUST-
05 (STs 274 and 781), AUST-06 (ST-801), AUST-07 (ST-
262), AUST-08 (STs 782, 783, 784 and 785) and AUST-09
(STs 274 and 1043), AUST-10 (STs 155 and 179), AUST-
11 (STs 803, 1034, 1037, 508, 804, 822 and 882), AUST-12
(ST-179), AUST-13 (STs 389 and 800), AUST-14 (STs 155
and 179), AUST-15 (ST-17), AUST-16 (ST-905), AUST-17
(ST-810), AUST-18 (ST-274), AUST-19 (STs 155 and
786), AUST-20 (ST-655), AUST-21 (STs 808), AUST-22
(ST-809), AUST-23 (ST-833), AUST-24 (ST-308), AUST-
25 (ST-274), AUST-26 (ST-179), AUST-27 (ST-455),
AUST-28 (ST-241), AUST-29 (ST-261), AUST-30 (ST-
1036), AUST-31 (ST-274), AUST-32 (ST-236), AUST-33
(ST-12), AUST-34 (ST-1038), AUST-35 (ST-553), AUST-
36 (ST-277), AUST-37 (ST-155), AUST-38 (STs 254 and
1041) [15], and international importance: LES (ST-146),
Manchester (ST-217), DK2 (ST-386), PA01 (ST-549), PA14
(ST-253), M18 (ST-1239), PACS2 (ST-1394), NCGM2.S1
(ST-235), PA7 (ST-1195), Clone C (ST-17), Dutch-1 (ST-
406), Dutch-2 (ST-497) and Midlands (ST-148) [17,19,20].
Statistical analysis
Discriminatory power and the quantitative measure of
congruence between the HRM10SNP and iPLEX20SNP
methods and corresponding 95% confidence intervals (CI)
were determined by calculating the Simpson’s Index of
Diversity and the adjusted Wallace coefficients respectively
using the online analysis tool at http://darwin.phyloviz.net/
ComparingPartitions/index.php?link=Tool. The 20-SNP pro-
file in-silico data were used to predict STs for the 506 clin-
ical isolates utilising the experimental results from the
iPLEX20SNP assay.
Results
In-silico analysis of MLST data
Analysis of the P. aeruginosa PubMLST website [17]
(13th December 2012) showed that the 1401 STs could
be divided into 927 different 20-SNP profiles (Additional
file 2: Table S2). Overall, 711 STs could be distinguished in-
dividually by the 20-SNP profile, whereas the remaining 690
STs had overlapping 20-SNP profiles with one (n = 120),
Table 1 Primers for primary PCR reaction for the
iPLEX20SNP
SNP site Genetarget Primers (5′-3′)
7 and 45 acsA
P1 10mer-ACCTTGTGCTTGTCGATGAT
P2 10mer-GCCACACCTACATCGTCTAT
322, 381 and 387 acsA
P1 10mer-ATCAGGTTGCCGAGGTTGTC
P2 10mer-AGACCGGCGCCTGCCTGATG






894 and 937 guaA
P1 10mer-AACATCGTCGACGACGCCAT
P2 10mer-AACACGCAGGTCAGTTGGTC









1865 and 1958 nuoD
P1 10mer-TACAGCAGGTGGTTCAGGAT
P2 10mer-AAGATGGCCGAGCGCCAGT









P1 = forward amplification primer;
P2 = reverse amplification primer;
10mer = 5′ 10-mer tagACGTTGGATG.
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two (n = 51), three (n = 13), four (n = 11), five (n = 6), six
(n = 2), seven (n = 2), eight (n = 1), nine (n = 2), ten (n = 4),
11 (n = 2), 12 (n = 1), or 13 other (n = 1) STs (Additional
file 2: Table S2). In total, 486/690 (70.4%) STs showing
overlapping 20-SNP profiles comprised closely related
single- or double-locus variant STs. Based on these data,
the D-value for the 20-SNP profiling method was cal-
culated as 0.999 (95% CI 0.998, 0.999). For the STs of
national and international importance, nine could be
distinguished individually by the 20-SNP profile, whereas
the remaining exhibited overlapping 20-SNP profiles.
Most of the latter were again single- or double-locus vari-
ant STs (Table 3 and Additional file 2: Table S2).
HRM10SNP and iPLEX20SNP typing of the 506 clinical
isolates
Application of the HRM10SNP assay provided complete
10-SNP profiles for 494/506 isolates (type-ability = 97.6%)
of which 92 different 10-SNP profiles were observed; 12
isolates were not typed using the HRM10SNP method as
one or more SNPs failed to be called by the HRM analysis
(Additional file 3: Table S3). The iPLEX20SNP assay pro-
vided complete 20-SNP profiles for 471/506 isolates (type-
ability = 93.1%) of which there were 147 distinct 20-SNP
profiles; 35 isolates failed to provide complete 20-SNP
profiles due to the iPLEX20SNP assay failing to character-
ise one or more SNPs (Additional file 3: Table S3). When
the 147 complete 20-SNP profiles (471 isolates) from the
iPLEX20SNP assay were used to predict a MLST type
(based on the data provided in Additional file 2: Table S2),
124 of 147 (84.4%) profiles matched profiles obtained
from the MLST website and there could provide a
predicted MLST type or types. Twenty-three 20-SNP
profiles from 28 isolates did not match with any of the
listed 20-SNP profiles in Additional file 2: Table S2, and
therefore a MLST type could not be predicted.
Overall, 470 isolates provided complete SNP profiles by
both the HRM10SNP and iPLEX20SNP assays. Simpson’s
Index of Diversity and adjusted Wallace coefficients be-
tween the HRM10SNP and iPLEX20SNP methods were
calculated using these 470 isolates (Table 4). Simpson’s
Index of Diversity of the iPLEX20SNP (0.947) was similar
to that of the HRM10SNP method (0.944). However, when
concordance between the assays was assessed using the
adjusted Wallace coefficient, the iPLEX20SNP method
(94.9%) was a better predictor of the HRM10SNP method
Table 2 Extension primers used for the iPLEX20SNP
SNP sitea Gene target UEP (5′-3′) Mass EP1, mass EP2, mass EP3, mass EP4, mass
7 acsA ACATCGTCTATGGCCCG 5146.4 C,5393.5 T,5473.5
45 acsA ggggTCTGTTCGAGGGCGT 5931.8 A,6203 G,6219
322 acsA gggtaGCGTGGGCGCCCGGCA 6529.2 T,6800.4 C,6816.4
381 ascA ttcccAGCCGTTCTTCGGCGTGGT 7302.7 C,7549.9 A,7573.9 G,7589.9 T,7629.8
387 ascA gaaGAGGTTGTCCACCAG 5548.6 G,5795.8 A,5875.7
416b aroE
TGCCGTTCAAGGAAGA
4930.2 C,5177.4 A,5201.4 G,5217.4
aGgCGTTCAAGGAACT
488 aroE ccCACCCTGATCCGCCT 5027.3 C,5274.5 G,5314.5 T,5354.4
881 aroE gagggTGTATGCCAAGGAACCGAC 7451.9 C,7699 G,7739.1 T,7778.9
894 guaA gTCCTCCAAGGTCCTGCT 5426.5 C,5673.7 A,5697.7 G,5713.7
937 guaA tgtTCcgCGATGGCCTTGTGCA 6733.4 T,7004.6 C,7020.6
1086 guaA gtCGAGGACAAGTTCCTCGG 6158 C,6405.2 G,6445.2 T,6485.1
1152 guaA ctcaGCACCTTCATCGAAGT 6036.9 C,6284.1 G,6324.2 T,6364
1297 mutL GTGGAAAGCCACGTCGAA 5557.6 T,5828.8 C,5844.8
1465 mutL gggCGGCtcGCACCTGTGGGG 6520.2 C,6767.4 T,6847.3
1865 nuoD agagaCAGTCtcGGCACAGTTTCAT 7666 C,7913.2 T,7993.1
1958 nuoD tgctGATCACGTCGACCCGCTG 6687.3 G,6934.5 C,6974.5
2169 ppsA ccggaGCGCTGGCCGATGGCACG 7091.6 G,7338.8 T,7362.8 C,7378.8 A,7418.7
2208 ppsA CCGACACGTCGTTGATCAC 5748.7 G,5995.9 A,6075.8
2337 ppsA CGCCGCGTGGCAGGT 4610 T,4881.2 C,4897.2
2551 trpE CAGATCCTGCTCCAG 4512.9 G,4760.1 C,4800.2 A,4840
Non-template bases are indicated in lower case. Mass (Daltons) is provided for the unextended extension primer (UEP), as well as associated extension products
(EP) 1, 2 and where relevant 3 and 4.
aSNP position is based on the 2882 bp concatenated sequence.
bNote that SNP 416 had two extension primers to accommodate a known proximal SNP variation.
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Table 3 P. aeruginosa MLST data from the P. aeruginosa MLST database website (13th December 2012) and associated
SNP profiles for STs of national and international importance





TGCAAGCTCCCCTTTGGGCG 242(AUST-03), 996 2 2/2 = SLVs
TGCCGGCTATCCCCCCGACA 787, 788(AUST-04) 2 2/2 = SLVs
TGTCGGCTACCTTTCGGGTA 209, 268, 274(AUST-05,-09, −18,-25, &-31) , 466, 546, 781(AUST-05),
936, 1043(AUST-09), 1068, 1089, 1301, 1326
12 12/12 = SLVs
CGCAAGCTATCCCCCGGGTG 4, 801 (AUST-06), 1292 3 2/3 = SLVs
CGCAAGCTATCCCCCCGGCA 262(AUST-07), 774, 1165 3 3/3 = SLVs
CGCAGGGCCCCCTTCGGGCG 782(AUST-08), 783(AUST-08), 784(AUST-08), 785(AUST-08) 4 4/4 = SLVs
CGCCGGCTCCCCCCCCGACA 179(AUST-10,-12,-14,&-26), 180, 353 3 3/3 = SLVs
TGCAAGCTACCCCCTGGACA 13, 155(AUST-10,-14, −19, &-37), 280, 541, 579, 677, 786(AUST-19), 1276, 1316, 1335 10 10/10 = SLVs
CGCAAGCTACCTCCCCGGTA 384, 1037(AUST-11) 2
CGCAGGCTACCTCCTGGGTG 508(AUST-11), 937 2 2/2 = SLVs
TGCCGGCTCCCCCCTGGGCA 554, 804(AUST-11) 2 2/2 = SLVs
CGCAGGCTACCTCCCCGGTA 589, 791, 803(AUST-11) 3 3/3 = SLVs
TGCCGGCTATCCCCCCGGCA 822(AUST-11), 1239(M18) 2 2/2 = SLVs




CGTCGGCTATCCTTCCGGTA 17(AUST-15 & Clone C), 318, 322, 380, 636, 688, 845, 958, 1255, 1313 10 9/10 = SLVs
CGCAAGCTACTCTCCCGGTG 905(AUST-16), 1039 2
CGTCGGCTATCCCCTGGGCA 398, 399, 401, 810(AUST-17) 4 3/4 = SLVs
CGTCGGCCACTCTTCCGGCG 655(AUST-20), 709 2 2/2 = SLVs
TGCAAGCTACCCTCCCGGTA 669, 808(AUST-21) 2 2/2 = SLVs
CGCCGGGCCTCCTCTGAGTG 809(AUST-22) 1
TGTCGGCTACCTTCCCGGTA 833(AUST-23), 839 2 2/2 = SLVs
TACCAGGCCCCCTCCGAGTG 89, 307, 308(AUST-24), 662, 1028 5 2/5 = DLVs
TGTCGGCCCCCCTTCGGGTA 455(AUST-27) 1
CGCAAGCTACCTTCCCGGTA 232, 241(AUST-28), 247, 379, 471, 577 6 5/6 = SLVs
CGTCGGCTATCCCCTGGGTA 169, 261(AUST-29) 2
CGCAGACTCCCCTCCCGGTA 1036(AUST-30) 1
TGCAAGCTATCCTCCCAGCG 236(AUST-32), 239, 240 3 3/3 = SLVs
TGCAAGCTATCCCCCCGGTG 12(AUST-33) 1
CGCAAGCTCCCCCCCGGGTA 103, 244, 441, 462, 464, 594, 766, 986, 1038(AUST-34), 1181, 1227, 1338 12 10/12 = SLVs or DLVs
CGCAAGCTATCCTTCCGGTA 445, 553(AUST-35) 2
CGCAAGCTCCTCTTTCGGTA 277(AUST-36), 364, 1128, 1390 4 4/4 = SLVs
TGTCGGCTCCTCTTTGGGTA 254(AUST-38), 1041(AUST-38) 2 2/2 = SLVs
TGTCGGCTACCTCCCCGGTG 146(LES), 374, 467, 681, 683, 970 6 6/6 = SLVs
TGCAAGCTACCTCCCCGACG 217(Manchester), 1134 2 2/2 = SLVs
CGCAAGCTACCTCCCCGGCG 386(DK2), 1244 2
TGCAGGCTCCCCCCCCAGCA 549(PA01), 1331 2 2/2 = SLVs
TATCGGGCCCCCTCCGAGTG 65, 107, 109, 253(PA14), 297, 338, 342, 377, 532, 773, 815, 923, 1110, 1363 14 3/14 = SLVs or DLVs
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than vice versa (89%). To investigate the latter further we
identified all 10-SNP profiles that were further discrimi-
nated by the 20-SNP profiles (Additional file 4: Table S4);
34 HRM10SNP profiles were further distinguished into
101 20-SNP profiles using the iPLEX20SNP method. Of
note, these involved 30 STs associated with CF strains
of local or international importance (Additional file 4:
Table S4). In contrast, there were only 11 iPLEX20SNP pro-
files that were further discriminated by the HRM10SNPassay
(Additional file 3: Table S3).
Given the high prevalence of AUST-01, AUST-02 and
AUST-06 in Australia, and that the HRM10SNP assay
was primarily designed to target these strains, we com-
pared the ability of both assays to distinguish these
strains. For isolates identified as AUST-01, AUST-02 or
AUST-06 by either method (Additional file 3: Table S3),
the results of the two methods were in agreement for
80/81 (98.8%), 48/49 (97.8%) and 11/12 (91.7%) isolates,
respectively. Both isolates giving discrepant results for
AUST-01 and AUST-06 were identified as AUST-01 or
AUST-06 by the iPLEX20SNP method, but not by the
HRM10SNP assay. For both of these isolates, their 10-
SNP profiles by the HRM10SNP differed by only one
SNP from the expected profiles of AUST-01 and AUST-06.
Upon repeat testing in the HRM10SNP assay, both subse-
quently typed as AUST-01 and AUST-06, suggesting that
there was a mistake in the original HRM10SNP testing.
The discordant result for AUST-02 was associated with a
different ST; one isolate was identified as AUST-02 by the
HRM10SNP method, but differed by two SNPs from the
expected 20-SNP profile for AUST-02 in the iPLEX20SNP
assay (predicted MLST type of 778).
Discussion
The in-silico analyses of sequence data from the P. aerugi-
nosa PubMLST website showed that more than half of
recognised STs could be distinguished individually by the
20-SNP profile of the iPLEX20SNP assay. Furthermore,
the recognised STs that were unable to be distinguished
by this assay were typically single- or double-locus vari-
ants. Hence, theoretically the iPLEX20SNP method has
considerable potential for broader-based MLST-focused
studies of P. aeruginosa, here and elsewhere. As the
iPLEX20SNP is also based on the Sequenom MassARRAY
platform, it is particularly suitable for high-throughput in-
vestigations [14]. Using this technology up to 384 isolates
can be tested within one working day for less than $AUD
10 per isolate [14], and is therefore quite favourable com-
pared to other technologies. For example, for our 506
test isolates we estimate that classical DNA sequencing-
based MLST would have cost approximately $AUS 60,720
($AUS 120 per isolate), whereas costs for the HRM10SNP
and iPLEX20SNP methods were approximately $AUS 10,120
($AUS 20 per isolate)13 and $AUS 5,060 respectively.
Compared to the HRM10SNP, the iPLEX20SNP method
clearly provided better discrimination when applied to the
P. aeruginosa test isolates used in this study. Of note was
that the HRM10SNP assay grouped numerous unrelated
isolates, including STs of shared strains in the CF patient
population, while the iPLEX20SNP method was able to
distinguish between these isolates (Additional file 4:
Table S4). This was likely due to the higher number of
SNPs and that SNP selection for iPLEX20SNP was based
on a large international MLST database. These observa-
tions provide experimental data to support the above
Table 3 P. aeruginosa MLST data from the P. aeruginosa MLST database website (13th December 2012) and associated
SNP profiles for STs of national and international importance (Continued)
CGTCGGCTCTCCCCTGGACA 1394(PACS2) 1
CGCTAGGCCCCCTCCGAGTG 227, 230, 235(NCGM2.S1), 533, 534, 696, 745, 976, 989 9 9/9 = SLVs
CGCGGAGCCCTCTCCGTGTG 366, 368, 1006, 1063, 1190, 1191, 1195(PA7) 7 4/7 = SLVs
CGTCGGCTACCTCCCCGACA 406(Dutch-1), 484, 519, 536, 547, 575, 608, 1214, 1235, 1312, 1318 11 10/11 = SLVs or DLVs
CGTCGGCTATCCTTTGGGTA 497(Dutch-2), 544, 895, 1317 4 4/4 = SLVs or DLVs
CGCAAGCTATCCCCCGAGTA 138, 140, 148(Midlands), 956 4 2/4 = SLVs
The STs consistent with recognised P. aeruginosa strains are indicated in parentheses.
aSNP profile is in the order of 7, 45, 322, 381, 387, 416, 488, 881, 894, 937, 1086, 1152, 1297, 1465, 1865, 1958, 2169, 2208, 2337 and 2551. These SNPs were
derived from the sequence data from the Pseudomonas aeruginosa MLST database website (http://darwin.phyloviz.net/ComparingPartitions/index.php?link=Tool)
on 13 December 2012. bMLST types available from the Pseudomonas aeruginosa MLST database website (http://pubmlst.org/paeruginosa) on 13 December 2012.
cSLV: single locus variant, DLV: double locus variant. dBoldface type represents previously characterised National and International MLST types of importance
(e.g., AUST-01 has the MLST type 649).
Table 4 Number of types, Simpson’s index of diversity and
adjusted Wallace coefficients for the HRM10SNP and
iPLEX20SNP assays calculated from application to the 470
isolates providing complete SNP profiles by both methods




(95% CI) (95% CI)
HRM10SNP 91 0.944 0.897
(0.933-0.955) (0.876-0.918)
20SNP iPLEX 147 0.947 0.949
(0.936-0.959) (0.912-0.986)
Syrmis et al. BMC Infectious Diseases 2014, 14:307 Page 6 of 8
http://www.biomedcentral.com/1471-2334/14/307
in-silico analyses. Indeed, in the clinical context, attaining
optimal discriminatory power is particularly important when
trying to identify new or emerging shared P. aeruginosa
strains in CF patients. Consequently, iPLEX20SNP is ideally
suited for broader, investigatory studies of P. aeruginosa
infected patients.
While the HRM10SNP lacked overall discriminatory
power, it nevertheless proved to be well-suited for
detecting AUST-01, AUST-02 and AUST-06 amongst
P. aeruginosa isolates from a broad range of Australian
CF clinics. AUST-01 and AUST-02 are the shared P. aer-
uginosa strains of greatest concern in Australia [15], and
therefore simple methods for detecting these strains
remain of local clinical and research interest. The one
key benefit of the HRM10SNP method is that it is
based on real-time PCR technology, which is now com-
monplace in most clinical microbiology laboratories.
Hence, the HRM10SNP method may still be a useful diag-
nostic tool locally for laboratories with no access to spe-
cialised equipment such as the Sequenom MassARRAY
platform.
Limitations in terms of typeability (i.e., the number of
isolates providing complete SNP profiles) were observed,
however, with 2.4% and 6.9% of isolates failing to give
complete profiles in the HRM10SNP and the iPLEX20SNP
assays respectively. Typically these problems are caused by
poor isolate preparation (i.e., insufficient DNA) or other-
wise sequence variation in primer targets [10,14]. Given
the sheer diversity amongst the P. aeruginosa MLST
housekeeping genes, it is highly likely that sequence vari-
ation would account for a large proportion of the problems
observed here. In any event, we do not see this as an im-
portant limitation affecting the broader utility of the assays
given that other methods, such as DNA sequencing, could
be applied if necessary to the small numbers of untypeable
isolates.
Conclusions
In summary, molecular typing is an integral part of investi-
gating the development and spread of shared P. aeruginosa
strain genotypes in patients with CF. The iPLEX20SNP is
a superior new method providing sufficient throughput
and discriminatory power for broader SNP-based MLST-
style investigations of P. aeruginosa, whereas the HRM10SNP
method remains a convenient technique for screening
CF clinical isolates for the current most commonly
shared Australian P. aeruginosa strains and should be
able to be performed by most clinical microbiology
laboratories.
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